Takeda’s Zasocitinib Delivers Strong Phase III Results in Plaque Psoriasis

Takeda has announced positive outcomes from two pivotal Phase III trials of zasocitinib, its once-daily oral tyrosine kinase 2 (TYK2) inhibitor for moderate-to-severe plaque psoriasis (PsO). The randomised, double-blind, multi-centre studies met all primary and secondary endpoints, demonstrating clear superiority over placebo and the active comparator apremilast.

After 16 weeks of treatment, zasocitinib achieved significant improvements in static Physician Global Assessment (sPGA 0/1) and Psoriasis Area and Severity Index (PASI 75), with clinical responses emerging as early as week four and continuing through week 24. All ranked secondary endpoints were also met, including PASI 90 and PASI 100, highlighting the drug’s potential to deliver near-complete or complete skin clearance in a convenient oral format.

Zasocitinib was generally well tolerated, with adverse events consistent with earlier studies. Based on these results, Takeda plans to submit a new drug application to the FDA and other regulators in 2026.

23-12-2025